Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience
Top Cited Papers
- 11 January 2025
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (4) , 322-328
Abstract
Background We report our experience of patients with generalised myasthenia gravis (gMG) treated with efgartigimod, an neonatal Fc receptor antagonist, under the Early Access to Medicine Scheme (EAMS) in the UK. Methods Data from all UK patients treated with efgartigimod under the EAMS July 2022 to July 2023 were collected retrospectively. Efgartigimod was administered as per the ADAPT protocol (consisting of a treatment cycle of four infusions at weekly intervals with further cycles given according to clinical need). Results 48 patients with acetylcholine receptor antibody-positive gMG were treated in 12 centres. Most (75%) were female and most had a disease duration of over 10 years. The average MG-Activities of Daily Living (ADL) score at baseline was 11.2. Most (72.9%) patients had undergone thymectomy. 77.0% were taking prednisolone at baseline. All patients had used non-steroidal immunosuppressant treatments, the average number tried was 2.6 (range 1–6). 51% had received rituximab. 54.2% of patients required regular intravenous immunoglobulin/plasma exchange. 75% of patients had a mean reduction in the MG-ADL of≥2 points in the first cycle and this remained stable throughout the study. The mean intracycle reduction in the MG-ADL score in the first, second, third and fourth cycles were −4.6 to –3.9, −3.4 and −4.2, respectively. Side effects were generally mild. No rescue treatments were required. At the end of the study, 96% of patients remained on efgartigimod. Conclusion Efgartigimod is a safe and effective treatment for patients with refractory, treatment-resistant gMG.Keywords
This publication has 14 references indexed in Scilit:
- Real-World experience with efgartigimod in patients with myasthenia gravisJournal of Neurology, 2024
- Efgartigimod in generalized myasthenia gravis: A real‐life experience at a national reference centerEuropean Journal of Neurology, 2024
- Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MGBMJ Open, 2023
- Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2022
- Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet Neurology, 2021
- ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumabJournal of Neurology, 2020
- Myasthenia gravis: new developments in research and treatmentCurrent Opinion in Neurology, 2017
- Randomized Trial of Thymectomy in Myasthenia GravisNew England Journal of Medicine, 2016
- International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15rMuscle & Nerve, 2016
- Less is more, or almost as much: A 15‐item quality‐of‐life instrument for myasthenia gravisMuscle & Nerve, 2008